Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Persistent Cancer Cells: The Deadly Survivors
Shensi Shen, Stéphan Vagner, Caroline Robert
Cell (2020) Vol. 183, Iss. 4, pp. 860-874
Open Access | Times Cited: 219

Showing 1-25 of 219 citing articles:

Metastasis
Stefanie Gerstberger, Qingwen Jiang, Karuna Ganesh
Cell (2023) Vol. 186, Iss. 8, pp. 1564-1579
Open Access | Times Cited: 348
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 773-791
Closed Access | Times Cited: 347
Metastasis-Initiating Cells and Ecosystems
Joan Massagué, Karuna Ganesh
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 971-994
Open Access | Times Cited: 241
Neoadjuvant therapy for pancreatic cancer
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 5, pp. 318-337
Closed Access | Times Cited: 205
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma
Yahaya A Yabo, Simone P. Niclou, Anna Golebiewska
Neuro-Oncology (2021) Vol. 24, Iss. 5, pp. 669-682
Open Access | Times Cited: 170
Persister cancer cells: Iron addiction and vulnerability to ferroptosis
Raphaël Rodriguez, Stuart L. Schreiber, Marcus Conrad
Molecular Cell (2021) Vol. 82, Iss. 4, pp. 728-740
Open Access | Times Cited: 168
Cancer cell plasticity during tumor progression, metastasis and response to therapy
Andrea Pérez-González, Kevin Bévant, Cédric Blanpain
Nature Cancer (2023) Vol. 4, Iss. 8, pp. 1063-1082
Open Access | Times Cited: 137
Cell–matrix interface regulates dormancy in human colon cancer stem cells
Yuki Ohta, Masayuki Fujii, Sirirat Takahashi, et al.
Nature (2022) Vol. 608, Iss. 7924, pp. 784-794
Closed Access | Times Cited: 128
Sublethal cytochrome c release generates drug-tolerant persister cells
Halime Kalkavan, Jinan Chen, Jeremy Chase Crawford, et al.
Cell (2022) Vol. 185, Iss. 18, pp. 3356-3374.e22
Open Access | Times Cited: 124
Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy
Masashi Mikubo, Yoshiaki Inoue, Geoffrey Liu, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 11, pp. 1798-1809
Open Access | Times Cited: 114
METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma
Manling Huang, Jianting Long, Zhijia Yao, et al.
Cancer Research (2022) Vol. 83, Iss. 1, pp. 89-102
Open Access | Times Cited: 112
Epithelial–mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities
Zhao Huang, Zhe Zhang, Chengwei Zhou, et al.
MedComm (2022) Vol. 3, Iss. 2
Open Access | Times Cited: 93
H3K27me3 conditions chemotolerance in triple-negative breast cancer
Justine Marsolier, Pacôme Prompsy, Adeline Durand, et al.
Nature Genetics (2022) Vol. 54, Iss. 4, pp. 459-468
Open Access | Times Cited: 79
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy
Adrián Álvarez-Varela, Laura Novellasdemunt, Francisco M. Barriga, et al.
Nature Cancer (2022) Vol. 3, Iss. 9, pp. 1052-1070
Open Access | Times Cited: 75
Inhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy
Zhe Zhang, Siyuan Qin, Yan Chen, et al.
EMBO Molecular Medicine (2022) Vol. 14, Iss. 2
Open Access | Times Cited: 69
Mitochondria and cell death
Hannah L. Glover, Annabell Schreiner, Grant Dewson, et al.
Nature Cell Biology (2024) Vol. 26, Iss. 9, pp. 1434-1446
Closed Access | Times Cited: 65
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Yi Pu, Lu Li, Haoning Peng, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 799-813
Closed Access | Times Cited: 61
New insights into the correlations between circulating tumor cells and target organ metastasis
Qinru Zhan, Bixia Liu, Xiaohua Situ, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 50
Cellular states are coupled to genomic and viral heterogeneity in HPV-related oropharyngeal carcinoma
Sidharth V. Puram, Michael Mints, Ananya Pal, et al.
Nature Genetics (2023) Vol. 55, Iss. 4, pp. 640-650
Closed Access | Times Cited: 49
Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung Cancer
Houssein Chhouri, David Alexandre, Luca Grumolato
Cancers (2023) Vol. 15, Iss. 2, pp. 504-504
Open Access | Times Cited: 43
Cellular adaptation to cancer therapy along a resistance continuum
Gustavo S. França, Maayan Baron, Benjamin R. King, et al.
Nature (2024) Vol. 631, Iss. 8022, pp. 876-883
Closed Access | Times Cited: 35
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
Franziska Haderk, Yu‐Ting Chou, Lauren Čech, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 30
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor
Warren Fiskus, Jessica Piel, Michael Collins, et al.
Blood (2024) Vol. 143, Iss. 20, pp. 2059-2072
Open Access | Times Cited: 18
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis
Sukanya Basu, Dong Yang, Rahul Kumar, et al.
Seminars in Cancer Biology (2021) Vol. 78, pp. 90-103
Open Access | Times Cited: 87
Evolving cancer–niche interactions and therapeutic targets during bone metastasis
Robert L. Satcher, Xiang H.-F. Zhang
Nature reviews. Cancer (2021) Vol. 22, Iss. 2, pp. 85-101
Open Access | Times Cited: 86
Page 1 - Next Page

Scroll to top